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Biomaterial-mediated modification of
the local inflammatory environment
Shane Browne and Abhay Pandit*
Network of Excellence for Functional Biomaterials (NFB), National University of Ireland, Galway, Ireland
Inflammation plays a major role in the rejection of biomaterial implants. In addition, despite
playing an important role in the early stages of wound healing, dysregulated inflammation
has a negative impact on the wound healing processes. Thus, strategies to modulate
excessive inflammation are needed. Through the use of biomaterials to control the release
of anti-inflammatory therapeutics, increased control over inflammation is possible in a
range of pathological conditions. However, the choice of biomaterial (natural or synthetic),
and the form it takes (solid, hydrogel, or micro/nanoparticle) is dependent on both
the cause and tissue location of inflammation. These considerations also influence the
nature of the anti-inflammatory therapeutic that is incorporated into the biomaterial to
be delivered. In this report, the range of biomaterials and anti-inflammatory therapeutics
that have been combined will be discussed, as well as the functional benefit observed.
Furthermore, we point toward future strategies in the field that will bring more efficacious
anti-inflammatory therapeutics closer to realization.
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Introduction
The inflammatory response is an essential part of the healing process (Martin and Leibovich, 2005;
Li et al., 2007). Inflammation is initiated by necrosis and tissue injury, through the recognition
of damage associated molecular patterns (DAMPs). DAMPs that trigger inflammation include
intracellular proteins and nucleic acids released by dying cells, and extracellular matrix (ECM)
fragments such as low molecular weight hyaluronic acid (HA) (Kataoka et al., 2014). In addition,
stores of inflammatory cytokines including IL-1α and IL-33 present in cells are released following
necrotic cell death (Chen and Nunez, 2010). Inflammation is required to remove necrotic and
apoptotic cells, cleaved ECM molecules, and to initiate subsequent angiogenesis and tissue repair
(Jiang and Liao, 2010). In fact, inflammatory cells have been shown to play a role in regeneration
(Kim et al., 2013). However, excessive and chronic inflammation leads to the formation of a hostile
environment for regeneration and repair, resulting in further cell death. Excessive inflammation
and ECM remodeling lead to the formation of a fibrotic scar through the upregulation of matrix
metalloproteinases (MMPs) and increased deposition of collagen type I and III (Dobaczewski
and Frangogiannis, 2008). This is typically characterized by increased neutrophils infiltration and
pro-inflammatory macrophage retention. This amplifies the pro-inflammatory cytokine response,
along with MMP activity and the presence of radical oxygen species (ROS). It has been shown
that improved wound healing occurs following a lesser inflammatory response in fetal wound
healing (Redd et al., 2004), with a reduced expression of pro-inflammatory cytokines, transforming
growth factor-beta (TGF-β), and overexpression of interleukin-10 (IL-10) (Lo et al., 2012). A similar
effect has been observed in fetal myocardium, with reduced inflammation allowing for complete
functional restoration (Herdrich et al., 2010). Furthermore, reduction in inflammation has been
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shown to promote mesenchymal stem cell (MSC)-mediated bone
tissue regeneration (Liu et al., 2011; Chang et al., 2013). While
scarless healing cannot be completely attributed to the absence of
inflammation, it does present evidence that a reduced inflamma-
tory response can result in a more favorable outcome.
Thus, strategies to reduce inflammation can prove to be of
benefit to treat conditions in which excessive inflammation causes
damage to the tissue, or when inflammation becomes chronic.
Biomaterials to Modulate Inflammation
Implanted biomaterials can cause an inflammatory response, with
the level of this response dependent on thematerial of choice along
with the site in the body into which it is implanted (Luttikhuizen
et al., 2006a,b; Anderson et al., 2008). This is known as the foreign
body response (FBR) and is the response of the host to the implant.
Following implantation, a biomaterial acquires a layer of host pro-
teins that is associated with the surface chemistry of the material.
This occurs before any interaction with host cells, and governs the
type of cells that interact and their phenotypes.Material properties
and, particularly, surface chemistry have an effect on protein
deposition on the surface. The proteins that typically absorb on
the surface include fibrinogen, albumin, and fibronectin. These
proteins form a provisional matrix composed mostly of fibrin
around the implant. This matrix acts like a thrombus and initiates
a wound healing-like inflammatory response. Inflammatory cells
such as neutrophils and macrophages are attracted by the build-
up of chemokines and other chemoattractants in the provisional
matrix. Therefore, the choice of biomaterial is of the utmost
importance, with an obvious preference for materials that cause
a minimal acute response. Typically, anti-inflammatory strate-
gies using biomaterials have involved loading of therapeutics
into biomaterial systems, with therapeutic release in vivo aiding
to alleviate inflammation. These anti-inflammatory signals are
composed of anti-inflammatory drugs, proteins, or nucleic acids,
while the delivery of stem cells has also been shown to result
in a reduced inflammatory response. In addition, a number of
naturally occurring biomaterials have intrinsic anti-inflammatory
signals. These include high molecular weight HA (Nakamura
et al., 2004; Hirabara et al., 2013) and chitosan, which have ROS-
scavenging properties (Je and Kim, 2006). However, in the case
of most materials, loading of anti-inflammatory therapeutics is
necessary to modulate the inflammatory microenvironment.
A wide variety of therapies to reduce inflammation exist, from
gene therapy to receptor blocking antibodies, protein delivery,
and cell therapy (see Figure 1B). However, as yet, no outstanding
candidate has emerged that can convincingly reduce inflamma-
tion in all situations. Each therapy has associated advantages and
disadvantages. However, the main drawback associated with most
therapies is inadequate efficacy as a result of an insufficient local
concentration. This may be due to minimal localization at the
appropriate site of action when administered systemically, or as
a result of clearance and destruction by inflammatory cells when
administered locally. One route to address this concern is by
the use of biomaterial systems as reservoirs of therapeutics to
locally deliver and sustain effective concentrations for a prolonged
period of time. Protein and gene delivery through scaffolds holds
much promise to produce efficacious therapies (O’Rorke et al.,
2010; Monaghan and Pandit, 2011; Censi et al., 2012). Natural
biomaterials are capable of loading and releasing therapeutics
through MMP-mediated biodegradation, with collagen in partic-
ular standing out for its usefulness (Browne et al., 2013). However,
synthetic materials may allow for increased control over degrada-
tion and release kinetics of therapeutics, with the caveat that the
material itself and its degradation products must cause a minimal
response when implanted in vivo.
A further consideration that must be taken into account is the
form the biomaterial system takes. Three typical structures that
biomaterials can take are solid scaffolds, hydrogels, and parti-
cles, shown in Figure 1A. The choice of biomaterial structure
is dependent on a number of factors, primarily the tissue being
targeted and also the nature of the anti-inflammatory therapeu-
tic incorporated. For example, solid scaffolds require surgery to
implant, and thus aremore suitable forwoundhealing applications
FIGURE 1 | Biomaterials to reduce inflammation: (A) biomaterial forms used to deliver therapeutics and (B) anti-inflammatory therapeutics that have
been delivered.
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in which they may be applied to an open wound. In contrast,
in situ gelling hydrogels and particles can typically be delivered
in a minimally invasive manner using a syringe without the need
for open surgery. Thus, hydrogels and particles are suitable for
delivery directly into tissues such as muscle and the myocardium.
However, in terms of loading, they differ. Particles are most suited
for protein, gene, and drug delivery (Sehgal and Srinivasan, 2009;
Browne et al., 2012; Kraskiewicz et al., 2013). Hydrogels may
not only be used for protein, gene, and drug delivery but also
for cells. Hydrogels can be designed to provide a microenviron-
ment that can be tuned to protect implanted cells, promoting
cell survival, and improving function (Seliktar, 2012). Mean-
while, solid scaffolds have also been loaded with proteins, nucleic
acids, and drugs, in addition to acting as matrices to enhance
cell transplantation (Thevenot et al., 2010; Holladay et al., 2011;
Hortensius et al., 2015). Thus, the choice of biomaterial form is
dependent on the tissue into which it will be implanted, and the
anti-inflammatory agent being delivered. The main biomaterial
approaches to reducing inflammation will be discussed in terms
of the type of biomaterial structure used.
Solid Scaffolds
The incorporation of stromal cell-derived factor-1 alpha (SDF-
1α) into a poly (lactic-co-glycolic acid) PLGA scaffold reduced
the inflammatory response when implanted into the subcuta-
neous space in mice (Thevenot et al., 2010). While SDF-1α is
typically associated with increased angiogenesis, it can also exert
anti-inflammatory effects through its mobilization and homing
effect on stem cells (Ceradini et al., 2004; Ceradini and Gurt-
ner, 2005). Thus, it was shown that incorporation of SDF-1α
in PLGA scaffolds reduced the inflammatory tissue response
through an increase in autologous stem recruitment to the implant
site. Furthermore, a reduction in pro-inflammatory cytokines was
detected, with reduced expression of a number of key mediators
including interleukin-1 alpha (IL-1α), interleukin-6 (IL-6), and
tumor necrosis factor alpha (TNF-α), while there was an increase
in vascular endothelial growth factor (VEGF) expression.
Modification of the inflammatory response to a carbodiimide
crosslinked collagen scaffold was achieved by codelivery of a plas-
mid encoding IL-10 (pIL-10). Treatment with the pIL-10 reduced
the inflammatory response to the implanted collagen scaffolds
in a subcutaneous model, with a reduction seen in infiltrating
macrophages (ED1 positive cells). However, a subsequent reduc-
tion in vascularization was also observed (van Putten et al., 2009).
A collagen scaffold withMSCs incorporatedwas further function-
alized with pIL-10 polyplexes in an effort to reduce inflammation
in an intramuscular model, and to promote the survival of the
MSCs. It was observed that pIL-10 polyplex treatment reduced
inflammation and increased MSC survival (Holladay et al., 2011).
When this system was implanted in a rodent model of myocar-
dial infarction (MI), reduced inflammation was detected along
with functional recovery of the heart, in terms of improved ejec-
tion fraction (Holladay et al., 2012). Furthermore, a change in
macrophage phenotype was detected. Macrophages were seen to
change from a classically activated, pro-inflammatory phenotype
in control groups to an alternatively activated, anti-inflammatory
phenotype following treatment with pIL-10 polyplexes andMSCs.
Macrophage phenotype has been shown to be a key component
of the inflammatory response to implanted biomaterials (van
Putten et al., 2013; Spiller et al., 2014), and thus strategies to
control the phenotype of macrophages may prove vital to mod-
ify inflammation. Incorporation of highly sulfated glycosamino-
glycans (GAGs) into collagen scaffolds has enabled the control
of monocyte differentiation and macrophage phenotype in vitro
(Kajahn et al., 2012). A reduction of pro-inflammatory cytokine
secretion and an increase in anti-inflammatory cytokines were
observed when primary macrophages were cultured with a col-
lagen scaffold containing highly sulfated GAGs, in comparison
with a collagen scaffold with either no GAGs incorporated or a
less sulfated GAG incorporated. However, the application of this
system in pre-clinical models is crucial to determine its potential
usefulness in controlling macrophage phenotype in disease states.
A silk-fibroin/HA scaffold was used to treat post-MI inflamma-
tion. In addition to providing a structural support to the damaged
myocardium, it was found that treatment with the composite silk-
fibroin/HA reducedmacrophage infiltration (CD68 positive cells)
in comparison with a non-treated infarct (Chi et al., 2012). In
addition, there was an increase in macrophages when bone mar-
row mesenchymal stem cells (BMSCs) were incorporated within
the scaffold. The authors attribute this to the fact that the cells were
obtained from male rats and transplanted in female rats. How-
ever, incorporation of the BMSCs improved myocardial function
(wall thickness and fractional shortening), primarily through an
increase in angiogenic factors and a resultant increase in vascular
area. This emphasizes that reducing inflammation is an important
factor, but that a multi-faceted approach is typically necessary
to ensure adequate healing. Conversely, it was found in a sepa-
rate study that a HA-based scaffold did not reduce inflammation
unless it was coupled withMSCs (Muscari et al., 2013). This could
be related to possible differences in the molecular weight of HA
used. An increase in the vascular density was observed with MSC
delivery, as with the previous study.
Delivery of ibuprofen from an electrospun, acid responsive poly
(L-lactide) (PLLA) scaffold improved regeneration in a muscle
woundmodel. Incorporation of sodium bicarbonate induced acid
responsiveness of the PLLA scaffold, as it was observed that
ibuprofen release was increased when the pH was changed from
7.4 to 5, whereas this property was not observed without the
incorporation of the sodium bicarbonate. It was found that the
ibuprofen reduced the inflammatory response as measured by
immunohistochemical staining and assessment of gene expres-
sion of IL-6 and TNF-α, which resulted in improved muscle
regeneration (Yuan et al., 2014). In a similar study, tetrandrine,
an anti-inflammatory agent, was incorporated into a PLLA scaf-
fold. It was found that this system could reduce the production
of pro-inflammatory cytokines both in vitro and in vivo (Wang
et al., 2014a). A subcutaneous study revealed that the tetrandrine-
loaded scaffold had a reduced inflammatory response compared
with the unloaded scaffold at 1, 4, and 12weeks.
Delivery of pIL-10 was proposed as a mechanism by which
to reduce the inflammatory response to porous poly (lactide-co-
glycolide) (PLG) scaffolds. It was found that a macrophage cell
line, RAW 264.7 cells, markedly reduced TNF-α and increased
IL-10 expression when cultured in the presence of the PLG
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scaffolds, the IL-10 gene, and lipopolysaccharide (LPS) (Gower
et al., 2014). This indicates a more anti-inflammatory nature of
the macrophages following treatment with the IL-10 gene-loaded
scaffold. Increased expression of IL-10 in vivo resulted in a reduc-
tion in leukocyte infiltration in the PLG scaffolds after 7 days. A
decrease was also observed in the expression of interferon gamma
(IFN-γ), but no difference was observed in the expression of IL-1β
or TNF-α when compared with the control scaffolds. A follow-on
study revealed that themechanism behind this anti-inflammatory
nature was a change in the phenotype of macrophages following
treatment with the pIL-10 gene. It was found that transduction of
RAW 264.7 macrophages with pIL-10 resulted in a switch toward
a more regulatory macrophage phenotype, as well as preventing
a shift toward a more inflammatory phenotype when in a pro-
inflammatory environment (IFN-γ andLPS) (Boehler et al., 2014).
A reduction in NF-kB activation was also observed following pIL-
10 delivery, which was consistent with the reduction observed in
TNF-α expression.
A sphingosine 1-phosphate receptor-3 agonist (FTY720) was
used to modify the inflammatory response to a PLGA film. It
was found that following implantation of a PLGA film, FTY720
delivery increased the arteriole and length density (Awojoodu
et al., 2013). This was found to be as a result of an increase
in the infiltration of anti-inflammatory monocytes to the site of
implantation. In vitro studies revealed that FTY720 treatment
changed the profile of inflammatory and regenerative cytokine
secretion in both pro- and anti-inflammatorymacrophages as well
as human umbilical vein endothelial cells (HUVECs).
The examples discussed above (summarized in Table 1) pro-
vide an overview of the range of therapeutics that have been
incorporated into solid biomaterial scaffolds. Therapeutics can
be added to the scaffold immediately prior to implantation, or
conjugated via linker systems. The incorporated therapeutics can
help to overcome inflammation associated with the FBR, as well as
any pre-existing pathological inflammation. The choice of thera-
peutic is dependent on the biomaterial itself, as well as the site into
which it will be implanted. Thus, it is imperative to consider each
pathology individually, rather than a ‘one size fits all’ approach.
Furthermore, depending on the context of the injury, as well as
the selected material, solid scaffold may be capable of providing
mechanical support, i.e., in the case of bone scaffolds, or functions
as a barrier in the case of dermal wounds.
Hydrogels
One of the main reasons why anti-inflammatory therapy has
become important in relation to biomaterials is to protect
implanted cells and prevent rejection by the host. This can be elu-
cidated with the example of islet cell delivery. Ideally, implanted
islet cells will not be rejected by the body, and can produce insulin
efficiently to correct diabetes. However, this is not the case in actu-
ality, as the host often rejects the implanted cells and their function
is compromised. Attempts to immuno-isolate cells using bioma-
terials have not proven successful, and thus anti-inflammatory
signals are necessary to prevent rejection by the host immune
system. Encapsulation in a biomaterial alone has not proved effi-
cacious, and thus the incorporation of anti-inflammatory agent
is the next logical step. Su et al. encapsulated islet cells in a
PEG-based hydrogel, and conjugated an inhibitory peptide to the
IL-1 receptor (IL-R1) (Su et al., 2010). This increased the survival
of encapsulated cells in vitro following exposure to IL-1β, IFN-γ,
and TNF-α, while islet cells were also able to continue glucose-
stimulated release of insulin when incubated with β-cell specific
T-lymphocytes.
Hyaluronic acid hydrogels have been extensively studied as
materials to deliver anti-inflammatory therapies due to their
biodegradable nature, as well as their own potential anti-
inflammatory nature, which is dependent on themolecular weight
chosen (Nakamura et al., 2004). Conjugation of dexamethasone to
the HAwas performed to increase drug retention by reducing dif-
fusion from the hydrogel (Ito et al., 2007). In vitro studies revealed
that the released dexamethasone reduced the expression of TNF-
α and IL-6 from LPS-treated macrophages in a dose-dependent
manner. Furthermore, in vivo studies showed that dexamethasone
conjugated hydrogels had a reduced inflammatory response after
2 days when implanted subcutaneously. In a similar study, an anti-
TNF-α antibody was conjugated to a HA hydrogel and applied to
a burn wound (Friedrich et al., 2014). This treatment appeared
to reduce the thickness of non-viable tissue, as well as IL-1β
concentration and macrophage infiltration compared with the
control.
Chitosan is a polysaccharide derived from crustaceans. It has
been used formany biomedical applications (Khor and Lim, 2003;
Jayakumar et al., 2010, 2007; Prabaharan, 2008). Specifically, it
is commercially available as a bandage due to its clotting ability
and its anti-bacterial properties (Chirkov, 2002). The addition
of adipose-derived mesenchymal stem cells (ADSCs) to a chi-
tosan hydrogel was seen to improve their survival in the infarcted
myocardium (Liu et al., 2012). In vitro studies demonstrated
the ROS scavenging properties of chitosan and its degradation
products. MI was induced by permanent ligation of the coronary
artery, followed by injection of the chitosan/ADSCs system. Treat-
ment with the chitosan/ADSCs system resulted in a reduction
in ROS, as observed by a reduction in dihydroethidium (DHE)
staining. An improvement was observed at 4weeks in ejection
fraction and fractional shortening, while there was a reduction
in apoptosis seen at 1week. Additionally, there was a reduction
in infarct size as well as an increase in wall thickness and ves-
sel density in the infarct site. This study demonstrates the anti-
ROS properties of chitosan, as it is hypothesized that chitosan
enhances stem cell retention and survival in the myocardium
(whichwas confirmedby in vivobioluminescence imaging), partly
due to its ability to scavenge ROS. This system was also uti-
lized to treat ischemic injury in the kidney (Gao et al., 2012).
A similar effect was observed, with a reduction in ROS expres-
sion, increased cell retention, and increased number of blood
vessels.
A large-scale study was performed to identify a suitable anti-
inflammatory drug for local immunosuppression of islet cells.
From a large range of anti-inflammatory drugs, curcumin was
identified as being capable of reducing inflammation and ensuing
fibrosis following implantation of PLGA particles (Dang et al.,
2013). Subsequent encapsulation of islet cells in alginate micro-
capsules, along with the identified anti-inflammatory curcumin,
improved survival of the islet cells in vivo, with reduced fibrosis
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TABLE 1 | Examples of anti-inflammatory therapies delivered from solid scaffolds.
Biomaterial
system
Therapeutic Dose In vitro characterization In vivo model In vivo outcome Reference
PLGA SDF-1α 50µg
SDF-1α
Stem cell migration assay Mouse
subcutaneous
implantation
Increased vessel density Thevenot
et al. (2010)Enhanced MSC engraftment
Reduced inflammatory response
(IL-1α, IL-6, TNF-α)
Collagen IL-10 pDNA 2.5µg IL-10
pDNA
n/a Rat subcutaneous
model
Reduced cell infiltration van Putten
et al. (2009)Reduced EDI+ cells
Reduced collagenase activity
Collagen IL-10 pDNA
polyplexes
and MSCs
2µg IL-10
pDNA
IL-10 secretion Rat intramuscular
implantation model
Increased stem cell survival Holladay
et al. (2011)Metabolic activity Increased ratio of regulatory to
inflammatory macrophages
Collagen IL-10 pDNA
polyplexes
and MSCs
2µg IL-10
pDNA
n/a Rat myocardial
infarction model
Improved cardiac function and stem
cell survival
Holladay
et al. (2012)
Increased ratio of regulatory to
inflammatory macrophages
Reduction in apoptosis
Silk-fibroin/
hyaluronic acid
n/a n/a n/a Rat myocardial
infarction model
Reduced CD68+ cells Chi et al.
(2012)Improved wall thickness and
fractional shortening
Reduced apoptosis
Increased vascular density, and
VEGF, bFGF, and HGF expression
Hyaluronic acid MSCs 0.2–1106 MSC proliferations Porcine myocardial
infarction model
Reduced CD3+ cells Muscari et al.
(2013)VEGF expression Reduced inflammatory score
Poly (L-lactide) Ibuprofen Not specified Ibuprofen release prolife in
neutral and acidic pH
Rat muscle wound
model
Improved muscle regeneration Yuan et al.
(2014)
Fiber diameter
Reduced IL-6 and TNF-α and IL-6
(protein and gene expression)
Increased VEGF and TGF-β (protein
and gene expression)
Poly (L-lactic
acid)
Tetrandrine 5–20mg/g Tetrandrine release Rat wound healing
model
Reduction in inflammation in
20mg/g tetrandrine group observed
on H&E stained sections
Wang et al.
(2014a,b)Cell viability
RAW 264.7 production of
NO, TNF-α, and IL-6 on
scaffold
Reduction in gene
expression of iNOS,
TNF-α, IL-6, and Cox-II
Poly (lactide-co-
Glycolide)
IL-10 viral
vector
2107 viral
particles
Reduced RAW 264.7
production of TNF-α and
increased IL-10 following
LPS treatment
Implantation into
intraperitoneal
mouse fat pad
Reduced leukocyte infiltration Gower et al.
(2014)Increased IL-10 expression and
reduced IFN-γ expression
Poly (lactic-co-
Glycolic acid)
film
FTY720 1:200 drug-
to-polymer
weight
Change in cytokine
secretion of RAW 264.7
and HUVEC
Dorsal skinfold and
muscle ischemia
models
Increase in presence of
anti-inflammatory macrophages
Awojoodu
et al. (2013)
Increased arteriole and length
density
of the capsules and improved glycemic control in a chemically
induced mouse type 1 diabetes model.
The anti-inflammatory drug resveratrol reduced inflammation
in a cartilage defect model when delivered via a collagen hydrogel
(Wang et al., 2014b). Resveratrol was grafted to poly (acrylic acid)
and incorporated within a type I collagen hydrogel. Following
delivery within a rabbit osteochondral defect model, treatment
with resveratrol reduced inflammatory gene expression (IL-1β,
MMP-13 and COX-2), with a resultant increase in bone and carti-
lage related genes (SOX-9, aggrecan, and collagen I and III). Gross
and histological examination revealed the formation of cartilage-
like neotissue, which compared favorably with no treatment and
a collagen hydrogel without resveratrol.
A gelatin hydrogel was loaded with an anti-inflammatory
peptide (triptolide) and BMP-2 to increase bone regeneration
(Ratanavaraporn et al., 2012). It was found that incorporation of
the anti-inflammatory peptide reduced the infiltration of inflam-
matory cells, except at the highest dose (10mg), which indicates
the importance of dose-response studies. Expression of IL-6, TNF-
α, and NF-kB mRNA was also reduced. Reduced infiltration
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of inflammatory cells resulted in an increase in bone forma-
tion and bone mineral density, when accompanied by BMP-2
delivery. This study highlights the possibility of combining anti-
inflammatory therapies with complementary therapeutics for the
treatment of complex pathologies. In this case, addition of an
osteoinductive protein, BMP-2, was essential for the formation
of bone, while reduced inflammation serves to enhance this
function.
A peptide nanofiber gel was loaded with dexamethasone to
modify the inflammatory response (Webber et al., 2012). In vitro
studies revealed that delivery of the dexamethasone from the
peptide nanofiber gel reduced NF-kB activation in LPS treated
THP-1monocytes. An in vivo subcutaneous study revealed that in
comparison with an unloaded peptide nanofiber gel, dexametha-
sone loaded gels reduced the presence of ROS and inflammatory
cells after 3 and 21 days.
A PEG-maleimide hydrogel was developed with on-demand
protease sensitive release of IL-1RA, the naturally occurring
antagonist to the IL-1R. This system was used as a coating
to reduce inflammation associated with implantation of neural
electrodes (Gutowski et al., 2015). Immunofluorescent staining
of inflammatory cell infiltration showed no difference between
samples, while RT-PCR analysis showed minimal differences,
with increases in IL-6, MMP-13, and ciliary neurotrophic factor
(CNTF) the only changes detected. However, the gene expression
analysis does allow for the specific-targeting of genes to reduce the
inflammatory response in future studies.
Hydrogels have been utilized for the delivery of a range of
anti-inflammatory therapeutics (see Table 2). Hydrogels have
proven particularly attractive as a matrix to assist cell transplan-
tation. They provide an ideal substrate for cell encapsulation
and protection from the host response. By engineering a suitable
matrix to encourage cell adhesion and proliferation, along with
the incorporation of an anti-inflammatory agent to be released
in the microenvironment, the survival of implanted cells can be
promoted.
Micro and Nanoparticles
Nanoparticles have been widely used to deliver anti-inflammatory
therapies. Whitmire et al. fabricated a new block copolymer that
assembles into sub-micron particles and contains a moiety for
tethering proteins (Whitmire et al., 2012). To this moiety, IL-
1RA was conjugated. These particles were injected into the intra-
articular joint space, where it was shown that they significantly
enhanced the retention time of IL-1RA. However, to further
increase retention time, the authors hypothesized that increased
particle size could prove beneficial. To achieve this, a new self-
assembling polymer composed of a polyhydroxyethylmethacry-
late (pHEMA) backbone with a functionalized hydrophobic side
chain of pyridine was fabricated, which allowed for variation in
particle sizes (Singh et al., 2014). Particles of size 500 and 900 nm
were fabricated and a fibronectin targeting ligand attached. Reten-
tion of BSA-loaded particles in the intra-articular space in the rat
stifle joint was assessed using fluorescence imaging. It was found
that the 900 nm particles were retained in the joint to a greater
extent that either the soluble protein or the 500 nm particles.
This emphasizes the importance of the design of appropriate and
efficient systems to deliver therapeutics.
Polymer particles fabricated from poly (cyclohexane-1,4-
diylacetone dimethylene ketal) (PCADK) were loaded with a p38
inhibitor to modulate the post-infarction inflammatory response
in the myocardium (Sy et al., 2008). In an intramuscular model,
the particles themselves were found to be non-inflammatory;
while in an MI model, the particles significantly reduced super-
oxide and TNF-α production. This resulted in a reduction in
fibrotic area as well as improved cardiac function. A similar study
utilized the same particles to deliver superoxide dismutase (SOD)
to the infarcted heart, which reduced superoxide expression and
apoptosis (Seshadri et al., 2010). A subsequent improvement in
cardiac function was also observed.
Encapsulating dexamethasone within PLGA particles reduced
the in vivo inflammatory response to PLGA particles (Dang et al.,
2011). It was found that encapsulation of dexamethasone within
PLGA particles reduced both coverage of the PLGA particles with
immune cells as well as cathepsin activity. Further investigation
of the infiltration of inflammatory cells by examining histological
sections revealed a reduction in the dexamethasone-loaded group
compared with the unloaded control. Methylprednisolone (MP)
was loadedwithin PLGAparticles in an attempt tomodify inflam-
mation following injury of the spinal cord. The PLGA particles
were suspended within an agarose gel to keep them in the local
microenvironment of the injury (Chvatal et al., 2008). It was
found that treatment withMP-loaded PLGA particles reduced the
number of activated maicroglia, as well as the expression of the
pro-inflammatory calpain and iNOS. This resulted in a reduction
in lesion volume, indicating the potential of anti-inflammatory
therapies in the spinal cord.
Delivery of siRNA targeting mitogen-activated protein kinase
kinase kinase kinase 4 (MAP4K4) via β1,3--glucan particles
suppressed systemic inflammation (Aouadi et al., 2009). Delivery
of the siRNA orally resulted in a reduction in MAP4K4 gene
expression in the lungs, liver, and spleen. In addition, when com-
pared to a scrambled siRNA, MAP4K4 reduced the presence of
LPS-induced TNF-α in both the serum and peritoneal fluid. The
administration of MAP4K4 siRNA reduced LPS-induced lethality
by inhibiting the expression of TNF-α and IL-1β. In a similar
study using the same glucan particles, siRNA targetingTNF-α and
osteopontin (OPN)was delivered systemically and localized to the
macrophages present in the adipose tissue (Aouadi et al., 2013).
It was found that silencing either TNF-α or OPN in the adipose
tissue improved the glucose tolerance in ob/ob mice. Similarly,
galactosylated trimethyl chitosanecysteine (GTC) nanoparticles
were conjugated with MAP4K4 siRNA and delivered orally to
treat ulcerative colitis (Zhang et al., 2013). It was found that
this treatment reduced MAP4K4 and TNF-α mRNA, as well as
TNF-α protein expression and MPO activity in the colon. Galac-
tosylated particles showed increased efficacy compared with non-
galactosylated nanoparticles, indicating the usefulness of targeting
activated macrophages.
Utilization of PLGA particles to deliver PEI-conjugated
FcγRIII-targeting siRNA to reduce inflammation proved effica-
cious in a rat model of temporomandibular joint (TMJ) inflam-
mation (Mountziaris et al., 2012). Meal pattern analysis revealed
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TABLE 2 | Examples of anti-inflammatory therapies delivered from hydrogels.
Biomaterial
system
Therapeutic Dose In vitro characterization In vivo model In vivo outcome Reference
PEG hydrogel
(10,000Mw)
IL-1R inhibitory
peptide (IL-1RIP)
1%
IL-1RIP
Cell viability and insulin secretion
from MIN6 cells
n/a n/a Su et al. (2010)
Hyaluronic acid Dexamethasone 2.2–4.4
10-5 M
Cell viability Subcutaneous
implantation
model
Reduced infiltration of
macrophages and neutrophils
observed on H&E stained
sections
Ito et al. (2007)
Hydrogel swelling ratio
Dexamethasone release profile
Reduced IL-6 and TNF-α
production by RAW 264.7
Hyaluronic acid Anti TNF-α
antibody
400µg/ml Binding affinity Rat burn models Reduced inflammatory cell
infiltration observed on H&E
stained sections
Friedrich et al.
(2014)
Reduced non-viable tissue
Reduced IL-1β protein
expression
Chitosan
hydrogel
ADSCs 4106
ADSCs
Cell adhesion and expression of
adhesion genes in response to
ROS
Rat myocardial
infarction model
Increased ICAM-1, VCAM-1,
and SDF-1 expression and
ADSC retention
Liu et al. (2012)
Reduction in ROS, apoptosis,
and infarct size
Increased wall thickness and
blood vessel density, improved
cardiac function
Chitosan
hydrogel
ADSCs 2106
ADSCs
n/a Rat acute renal
ischemia-
reperfusion
model
Reduction in apoptosis and
ROS expression
Gao et al.
(2012)
Increased stem cell retention
and renal cell proliferation
Reduction in serum levels of
creatinine and blood urea
nitrogen
Alginate
microcapsules
containing islet
cells
Curcumin 1mg/ml n/a STZ-induced
diabetic mouse
model
Improved blood glucose level Dang et al.
(2013)Reduced gene expression of
CD68, CD19, CD74, CD8,
TNF-α, TGF-β, and αSMA
Collagen
hydrogel
Resveratrol 0.5% Compressive strength free
radical scavenging
Rabbit
osteochondral
defect
Reduction in IL-1β, MMP-13,
and Cox-II mRNA
Wang et al.
(2014a,b)
Collagen degradation Increased SOX-9, aggrecan,
collagen I and III mRNA
Cell viability Improved neotissue formation
and integration
Increased collagen II deposition
Gelatin Triptolide [and
BMP-2]
2.5, 5, or
10mg
Release profile Rat critical-sized
bone defect
Reduced lymphocytes,
netrophils, and mast cells
Ratanavaraporn
et al. (2012)Relationship between
degradation and release profile
Reduction in IL-6 and IL-10
protein expression in J774.1
macrophage-like cells
Reduced mRNA expression of
IL-6, IL-10, TNF-α, NF-kB, and
MMP-14
Proliferation and ALP activity in
MC3T3-E1 cells
Increased bone mineral density
Peptide
amphiphile
Dexamethasone Not
specified
Dexamethasone release Mouse
subcutaneous
model
Reduced ROS formation Webber et al.
(2012)Reduced NF-kB activity in THP-1
cells following LPS activation
Reduced inflammatory cell
infiltration observed on H&E
stained sectionsCell viability following treatment
with Dex-PA
Poly (ethylene
glycol)-
maleimide
(Coating on a
neural electrode)
IL-1RA 150pg Coating thickness Rat neural
implantation
model
Increased IL-6, MMP-2, and
CNTF
Gutowski et al.
(2015)Cell adhesion
Reduced expression of IL-1β and
TNF-α in microglia/astrocytes
treated with GMCSF
IL-1RA release profile
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an improvement following FcγRIII siRNA treatment, while a
reduction was observed in the levels of two key pro-inflammatory
cytokines, IL-1β and IL-6. Similarly, PLGA particles were used
to delivery anti-TNF-α siRNA to treat inflammation associated
with rheumatoid arthritis (RA) (Présumey et al., 2012). In vitro
studies revealed that delivery of anti-TNF-α siRNA via PLGA
particles could reduce LPS-induced TNF-α production in mouse
monocytic J774 cells. Translation to an in vivo model of RA
resulted in a reduction in TNF-α production and inflammation
in the joint. Loading of PLGA particles with COX-2 siRNA and
dexamethasone has also been proposed as a means by which to
modify RA associated inflammation (Park et al., 2012). PLGA
particles were loaded with dexamethasone, and then these drug-
loaded particles had PEI/siRNA complexes attached to them. Pre-
treatment of C28/I2 cells with TNF-α and IL-1β in vitro resulted
in increased expression of COX-2 and iNOS. However, treatment
with PLGA particles combined with dexamethasone and COX-
2 siRNA reduced this induced expression. Interestingly, it was
observed that dexamethasone had a minimal effect on inflamma-
tory gene expression unless it was delivered via PLGA particles.
This emphasizes the importance of the mode of delivery of an
anti-inflammatory therapy, and suggests biomaterial systems as
reservoirs of such therapeutics.
An annexin-A1 mimetic-peptide (Ac2-26) showed increased
efficacy, when loaded within nanoparticles. Nanoparticles were
fabricated from a biodegradable PLGA-b-PEG polymer using a
nanoprecipitation method, with a collagen IV-targeting conjugate
(Kamaly et al., 2013). These targeting nanoparticles loaded with
Ac2-26 showed an increased ability to reduce the number of
macrophages in an in vivo murine peritonitis model compared
with non-targeting particles, srambled peptide-loaded particles,
and also non-loaded particles. In an in vivo model of ischemia,
targeted particles again compared favorably with scrambled-
peptide loaded targeting particles and also non-targeting peptide
loaded particles, with a reduction observed in myeloperoxidase
activity. A similar formulation, but without the collagen IV-
targeting conjugate, was used to form nanoparticles and deliver an
anti-inflammatory synthetic liver X receptor agonist (GW3965)
(Gadde et al., 2014). In peritoneal macrophages in vitro, it was
shown that treatment with GW3965 in nanoparticle form reduced
expression of monocyte chemoattractant protein 1 (MCP-1) and
TNF-α. In an in vivo model of peritonitis, a reduction was
observed in macrophage numbers, and MCP-1 and TNF-α gene
and protein expression at a similar level to dexamethasone
treatment.
A lipid nanoparticle was used to deliver a therapeutic siRNA
that reduced the accumulation of pro-inflammatory monocytes
to inflamed tissue (Leuschner et al., 2011). An siRNA targeting
the chemokine receptor CCR2was administered systemically, and
shown to reduce the infarct size in anMImodel, reduce inflamma-
tory cells in atherosclerotic lesion, improve the survival of pancre-
atic islet allografts, and reduce tumor volume. This emphasizes the
power of siRNA as a therapeutic modality capable of controlling
cell phenotype, in this case pro-inflammatory macrophages.
Urethane acrylate non-ionomer (UAN) nanoparticles were
functionalized with a targeting moiety to increase localization to
tumors (Park et al., 2013). By conjugating an ICAM-1 targeting
ligand to nanoparticles, localization to tumors and inflamed tissue
was increased. UAN nanoparticles loaded with paclitaxel reduced
the tumor volume compared without a targeting ligand. This
shows the potential to target inflammation with nanoparticles
and a targeting moiety. This system could be adapted to load
various therapeutics, and also conjugated with different ligands
for targeting of specific sights.
PLGA and chitosan were used to form bilayered nanoparticles
for the delivery of two anti-inflammatory drugs, spantide II (SP)
and ketoprofen (KP) (Shah et al., 2012). These nanoparticles
were combined with a skin-permeating nanogel, and used in
two models of allergic contact dermatitis (ACD) and psoriatic
plaque. Ear thickness was reduced in the ACDmodel, while trans-
epidermal water loss was reduced in the psoriatic model, the
two primary endpoints in both models, indicating the power of
anti-inflammatory delivery via nanoparticles.
Particulate systems, whether in the micro or nano range, are
versatile delivery systems capable of delivering drugs, proteins,
and nucleic acids, or combinations thereof (see Table 3). How-
ever, issues with retention at the inflamed site persist, amplified
by the fact that activated macrophages clear particles in a size
and shape-dependent manner (Champion and Mitragotri, 2006).
Thus, choice of particle size/shape is imperative, as well as other
strategies to avoid uptake and clearance. These may include teth-
ering of “self ” peptides to particles (Rodriguez et al., 2013), or
combination with solid or hydrogel scaffolds to increase bulk
retention in the target tissue.
Future Directions
Modulation of inflammation is a key component for the success
of biomaterial and tissue engineering based strategies. This is the
case both in terms of modulating the FBR to ensure the survival
and functionality of implanted devices and also in delivering anti-
inflammatory therapeutics to sites of pathological inflammation.
Thus, strategies to improve the efficacy of anti-inflammatory
therapies are vital.
The inflammatory response is often quantified in terms of
the number of macrophages present, the phenotype of these
macrophages, or both. Thus, themacrophage is and has been iden-
tified as a key component of inflammation (Wynn and Barron,
2010; Koh and DiPietro, 2011) and the FBR to biomaterials (Xia
and Triffitt, 2006; Brown et al., 2012). Furthermore, where along
the spectrum of macrophage activity, these macropahages are a
key determinant inwhether inflammationwill become resolved in
a satisfactory manner (Mosser and Edwards, 2009). Thus, control
over macrophage can be key to modulating inflammation and
resolving it. Cytokines such as IL-4, IL-10, and IL-13 (seeFigure 2)
have been identified as playing a role in shifting the balance from a
pro-inflammatorymacrophage to that of amacrophagemore anti-
inflammatory in nature, promoting tissue repair and remodeling
(Mantovani et al., 2013). A number of biomaterial systems have
been developed to deliver pDNA to macrophages (Helary et al.,
2012; Mahor et al., 2012). Thus, specific delivery of molecules
to direct macrophages toward an anti-inflammatory phenotype
rather than a pro-inflammatory phenotype holds promise as a
treatment for inflammation.
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TABLE 3 |Micro and nanoparticles used to deliver anti-inflammatory therapies.
Biomaterial
system
Therapeutic Dose In vitro
characterization
In vivo model In vivo outcome Reference
Tetraethylene glycol
and cyclohexyl
methacrylate
nanoparticles
IL-1RA 5µg IL-1RA Nanoparticle size Rat
intra-articular
model
Increased retention of IL-1RA
compared with saline delivery
Whitmire
et al. (2012)Target specificity
NF-κβ activity in NIH3T3
fibroblasts
Poly (hydroxy-ethyl-
methacrylate)
[p(HEMA)]
(BSA as a model
protein)
500µg
Vivo-Tag-
S750-BSA
Particle size
Cell viability
Rat
intra-articular
injection
Increased retention compared with
soluble protein
Singh et al.
(2014)
Poly (cyclohexane-
1,4-diylacetone
dimethylene ketal)
(PCADK)
P38 inhibitor 50µg P38
inhibitor
Particle size
Activation of RAW 264.7
macrophages
Rat myocardial
infarction model
Reduced P38 activation,
superoxide, and TNF-α production
Sy et al.
(2008)
Reduced fibrotic area and
improved cardiac function
Poly (cyclohexane-
1,4-diylacetone
dimethylene ketal)
(PCADK)
Superoxide
dismutase
(SOD)
80U SOD Particle size Rat myocardial
infarction model
Reduced superoxide production
and apoptosis
Seshadri
et al. (2010)
Superoxide scavenging Improved cardiac function
PLGA Dexamethasone 1.3 and 26
wt%
Dexamthasone loading and
release
Mouse
subcutaneous
injection
Reduced cathepsin activity up to
10days
Dang et al.
(2011)
Reduced inflammatory cell
infiltration up to 30 days
PLGA Methylprednisolone 156µg Methylprednisolone release Rat spinal cord
contusion model
Reduced ED1+ cells Chvatal et al.
(2008)NO production by
LPS-treated microglia
Reduced Calplain and iNOS
Reduced lesion volume
β1,3-d-glucan MAP4K4 siRNA 20µg/kg
body weight
MAP4K4 and TNF-α
knockdown
Mouse
LPS-induced
lethality
Reduced MAP4K4 mRNA in
peritoneal macrophages, spleen,
liver, and lung
Aouadi et al.
(2009)
Reduced TNF-α and IL-1β mRNA
Reduced serum and peritoneal
TNF-α
Galactosylated
Trimethyl
Chitosanecysteine
MAP4K4 siRNA 250µg/kg
body
weight/day
Charge and cell uptake Mouse
ulcerative colitis
MAP4K4 and TNF-α mRNA
knockdown
Zhang et al.
(2013)
MAP4K4 and TNF-α mRNA
knockdown
Reduced colonic TNF-α protein
and MPO activity
Reduced TNF-α protein
expression
Reduced infiltration of
mononucleur cells observed on
H&E sections
PLGA FcγRIII-targeting
siRNA
16–23µg siRNA release Rat temporo-
mandibular
inflammation
Reduced IL-1β and IL-6 protein
expression
Mountziaris
et al. (2012)
siRNA loading efficiency Reduced FcγRIII expression
PLGA TNF-α siRNA 0.12 nM Particle size
siRNA release
Mouse collagen
induced arthritis
Reduced synovial inflammatory
score
Présumey
et al. (2012)
Reduced TNF-α mRNA and
protein expression
Reduced TNF-α protein
expression
PLGA Dexamethasone
and COX-2
siRNA
n/a Dexamethasone and siRNA
loading
n/a n/a Park et al.
(2012)
Particle size, charge, cell
viability, uptake, and
transfection efficiency
PGE2 secretion
COX-2 and iNOS knockdown
in C28-I2
Reduced mPGES-1, COX-2,
and iNOS protein expression
Reduced caspase-3
PLGA-b-PEG Ac2-26
(annexin-A1
mimetic peptide)
100 ng Particle size Murine
peritonitis
Reduced number of PMNs Kamaly et al.
(2013)
Ac2-26 release Muscle ischemia Reduced MPO activity
(Continued)
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TABLE 3 | Continued
Biomaterial
system
Therapeutic Dose In vitro
characterization
In vivo model In vivo outcome Reference
PLGA-b-PEG GW3965 (liver X
receptor
agonist)
8mg/kg Particle size Mouse
zymosan-
induced
Peritonitis
Reduced PMN infiltration Gadde et al.
(2014)GW3965 release profile Reduced TNF-α and MCP-1 gene
and protein expression in
peritoneal exudates
Reduced TNF-α and MCP-1
gene and protein expression
in peritoneal macrophages
C12-200 lipid, dis-
teroylphosphatidyl
choline, cholesterol,
and PEG-DMG
CCR2 siRNA 1mg/kg n/a Mouse
ischemia/
reperfusion
Reduced CCR2 expression Leuschner
et al. (2011)
Mouse
permanent
ligation
Reduced myocardial area-at-risk
Mouse
streptozotocin-
induced
diabetes
Reduced Ly-6Chigh macrophages,
CD11b+ cells, and lesion volume
in atheresclerotic plaque
Mouse islet
transplantation
Increased survival of pancreatic
islet allografts
Mouse tumor
xenograft model
Reduced tumor volume, tumor
associated macrophages, and
CD11b+ cells
Urethane acrylate
non-ionomer (UAN)
Paclitaxel 200µg UAN-
Paclitaxel
nanoparti-
cles
Viability and dose response Mouse tumor
cytotoxicity
assay
Reduced tumor volume Park et al.
(2013)
PLGA and chitosan Spantide II and
ketoprofen
Not specified Particle loading efficiency Mouse allergic
contact
dermatitis
Increased drug retention Shah et al.
(2012)Spantide II and ketoprofen
release profile
Reduced ear
Reduced IL-17 and IL-23
expression
Reduced trans-epidermal water
loss
FIGURE 2 |Macrophage phenotype: inflammation may be controlled by
modulation of the phenotype from a pro-inflammatory nature to
anti-inflammatory and wound healing. Cytokines including IL-4, IL-10, and
IL-13 have been implicated in the transition of macrophages from a
pro-inflammatory phenotype to a more regulatory, anti-inflammatory and wound
healing phenotype in vivo.
A number of natural biomaterials have intrinsic anti-
inflammatory properties, including HA and chitosan. Thus,
they are suitable as carriers for anti-inflammatory therapeutics.
However, synthetic materials are also capable of acting in an
anti-inflammatory way. Dead and dying cells release their
contents, including nucleic acids, both RNA and DNA. These
nucleic acids act as DAMPs and activate toll like receptors (TLRs),
stimulating an inflammatory response. It was found that binding
of nucleic acids produced by injury by cationic polymers reduces
associated inflammation, both in vitro and in vivo (Lee et al.,
2011). This ability to act as a molecular scavenger for nucleic
acids could be adapted for other molecules, with a biomaterial
acting as a “sponge” to scavenge and absorb pro-inflammatory
cytokines in an inflamed environment. However, a more specific
approach, possibly involving conjugation of pro-inflammatory
targeting antibodies, would be necessary to avoid the uptake of
all cytokines and growth factors. In a similar way, materials may
be protected from an inflammatory response by the conjugation
of immunomodulatory “self ” proteins. Attachment of CD200
protein to a biomaterial surface reduced the production of TNF-α
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and IL-6 in vitro in response to LPS and IFN-γ stimulation, by
activating pathways that inhibit inflammation (Kim et al., 2014).
This anti-inflammatory nature was confirmed in vivo using bio-
luminescence imaging to detect ROS activity. In comparison with
unmodified materials, the CD200 modified material displayed a
drastically reduced tissue response. Strategies such as this may
reduce inflammation in the context of implantable devices, but
may also be used as a means by which to reduce inflammation
locally in a pathological condition.
Nanoparticles can be used to deliver multiple therapeutics.
Codelivery of IL-10 siRNA and a pDNA vaccine using PLGA-
PEI nanoparticles were used to modify the Th1 to Th2 balance
during immunotherapy (Singh et al., 2008). Similarly, lipid-like
nanoparticles were used to simultaneously deliver both pDNAand
siRNA (Dong et al., 2014). In vivo studies showed the potential to
upregulate luciferase activity and reduce Tie-2 expression using a
luciferase pDNA, and a Tie-2 targeting siRNA. Selection of dif-
ferent nucleic acids creates an opportunity to upregulate an anti-
inflammatorymediatorwhile knocking down a pro-inflammatory
mediator concurrently. This may prove key as inflammation is
a complex phenomenon that requires multiple points of con-
trol.
Responsive systems are a well-utilized facet of biomaterial
design. In order to design biodegradable systems, crosslinkers
with MMP-cleavable sequences are incorporated into typically
non-degradable sequences. In this way, MMP sensitivity is built
into the system. Therapeutics may also be conjugated to biomate-
rials using sensitive linker systems. That is, the therapeutic will be
released in response to a pre-determined stimulus. For example,
previously therapeutics have been conjugated to a fibrin scaffold
such that they would only be released by MMP activity, resulting
in improved efficacy (Zisch et al., 2003; Ehrbar et al., 2004). ROS
sensitivity has been identified as a key mediator for the release of
therapeutics (Yoshitomi andNagasaki, 2014). Nanoparticles com-
posed of β-cycoldextrin were engineered with ROS sensitivity,
and tested in vitro and in vivo. ROS responsive-release of docetaxal
from nanoparticles in vivo was assessed as a means by which to
reduce tumor volume (Zhang et al., 2015).
As stated, inflammation is a key determinant in the FBR and
how it progresses. In addition, in plays a key role in the progression
of a number of pathological conditions in which it is dysreg-
ulated. However, in most cases, dysregulation of and excessive
inflammation is not the only process involved. For instance, in
the case of diabetic wound healing, inflammation is excessive, but
there are also issues with insufficient angiogenesis as well as ECM
turnover. Thus, approaches that aim to reduce inflammation and
also modulate other processes are needed. Biomaterial systems
can be designed to load and release multiple, complementary
therapeutics (Browne and Pandit, 2014). A multi-modal system
composed of fibrin microspheres in a fibrin hydrogel was used
to modify inflammation and angiogenesis, through the delivery
of two pDNAs encoding Rab18 and endothelial nitric oxide syn-
thase (eNOS) (Kulkarni et al., 2014). This improved healing in
a diabetic rabbit wound model. A similar system composed of
collagen spheres-in-hydrogel was used to deliver IL-10 and eNOS
pDNA in a staggered manner in vitro (Alexander et al., 2013),
while in vivo assessment of dual delivery of anti-inflammatory and
pro-angiogenic peptides showed a combinatorial effect (Zachman
et al., 2012).
Outlook
Control over inflammation is vital for the success of biomaterial
and tissue engineered therapies. Modification of inflammation is
key to reducing the impact of the FBR. In addition, biomaterials
also offer the opportunity to control inflammation in patholog-
ical conditions, through increased localization and retention of
therapies in the inflamed microenvironment. The form of bio-
material used (solid scaffold, hydrogel, or micro/nanoparticle) is
dependent on the target site, with considerations such as ease of
access and retention paramount. In addition, the choice of anti-
inflammatory therapeutics is typically dependent on the cause of
inflammation.
Future therapeutics will focus on control of macrophage phe-
notype, the use of anti-inflammatory materials, complementary
combinations of anti-inflammatory therapeutics, and biomaterial
systems that release anti-inflammatory therapeutics in response
to inflammatory stimuli, such as ROS and MMPs.
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